Background Porphyria cutanea tarda (PCT) is the most common human porphyria. It is caused by hepatic deficiency of uroporphyrinogen decarboxylase activity, which is acquired in the presence of multiple susceptibility factors. PCT presents clinically with cutaneous blistering photosensitivity and is readily treatable with either repeated phlebotomy or 4-aminoquinoline antimalarials. Objectives To perform a systematic review and meta-analysis to compare the effectiveness of these quite different treatment approaches, especially on relapse rates (RRs) after achieving remission. Methods Published studies that included follow-up for at least 1 year after treatment of PCT were included. The primary study outcome was PCT relapse. Pooled data are reported as the RRs per person-year of follow-up with 95% confidence intervals (CIs). Results Of 375 articles identified as pertaining to PCT treatment, 12 were eligible for analysis. Of these, five used high-dose 4-aminoquinoline regimens (two combined with phlebotomy and three without phlebotomy), five used low-dose 4-aminoquinoline regimens and three used phlebotomy. RRs during the year after treatment were similar for the high-and low-dose 4-aminoquinoline groups (35-36%) and lower in the phlebotomy group (20%). The pooled RRs with their 95% CIs were 8Á6 (3Á9-13Á3) per 100 person-years in the high-dose 4-aminoquinoline group, 17Á1 (8Á9-25Á3) per 100 person-years in the low-dose 4-aminoquinoline group and 5Á1 (0Á5-10Á6) per 100 person-years in the phlebotomy group. Subgroup and sensitivity analyses showed similar results. Conclusions Clinical or biochemical RRs ranged from 5 to 17 per 100 person-years after remission of PCT. Relapses were somewhat more frequent after remission with 4-aminoquinoline regimens than after remission following phlebotomy. Prospective studies are needed to define better how often relapses occur with these treatments after documenting both clinical and biochemical remission of PCT.
Summary
Background Porphyria cutanea tarda (PCT) is the most common human porphyria. It is caused by hepatic deficiency of uroporphyrinogen decarboxylase activity, which is acquired in the presence of multiple susceptibility factors. PCT presents clinically with cutaneous blistering photosensitivity and is readily treatable with either repeated phlebotomy or 4-aminoquinoline antimalarials. Objectives To perform a systematic review and meta-analysis to compare the effectiveness of these quite different treatment approaches, especially on relapse rates (RRs) after achieving remission. Methods Published studies that included follow-up for at least 1 year after treatment of PCT were included. The primary study outcome was PCT relapse. Pooled data are reported as the RRs per person-year of follow-up with 95% confidence intervals (CIs). Results Of 375 articles identified as pertaining to PCT treatment, 12 were eligible for analysis. Of these, five used high-dose 4-aminoquinoline regimens (two combined with phlebotomy and three without phlebotomy), five used low-dose 4-aminoquinoline regimens and three used phlebotomy. RRs during the year after treatment were similar for the high-and low-dose 4-aminoquinoline groups (35-36%) and lower in the phlebotomy group (20%). The pooled RRs with their 95% CIs were 8Á6 (3Á9-13Á3) per 100 person-years in the high-dose 4-aminoquinoline group, 17Á1 (8Á9-25Á3) per 100 person-years in the low-dose 4-aminoquinoline group and 5Á1 (0Á5-10Á6) per 100 person-years in the phlebotomy group. Subgroup and sensitivity analyses showed similar results. Conclusions Clinical or biochemical RRs ranged from 5 to 17 per 100 person-years after remission of PCT. Relapses were somewhat more frequent after remission with 4-aminoquinoline regimens than after remission following phlebotomy. Prospective studies are needed to define better how often relapses occur with these treatments after documenting both clinical and biochemical remission of PCT.
What's already known about this topic?
• Porphyria cutanea tarda (PCT) is a chronic disease with potential for relapse.
What does this study add?
• The relapse rate of PCT based on this meta-analysis is about 5-17 per 100 personyears of follow-up after achieving remission.
• The relapse rate is somewhat higher after remission with 4-aminoquinolines, especially using a low-dose regimen, compared with remission after phlebotomy.
Porphyria cutanea tarda (PCT) is the most common human porphyria. It is due to an acquired deficiency of hepatic uroporphyrinogen decarboxylase (UROD) activity, resulting in accumulation of uroporphyrinogen and other highly carboxylated porphyrinogens in the liver, which then enter the plasma mostly as oxidized porphyrins and are excreted in the urine. 1 Elevated levels of these porphyrins in plasma cause chronic blistering cutaneous photosensitivity affecting sun-exposed areas. Deficient activity of hepatic UROD results from inhibition by a uroporphomethene, 2 which is generated from uroporphyrinogen by an oxidative process in the presence of iron and susceptibility factors. These factors may include alcohol, smoking, hepatitis C virus (HCV) infection, oestrogen use, haemochromatosis gene mutations and HIV infection. Approximately 20% of patients are heterozygous for UROD mutation, which reduces UROD to 50% of normal levels in all tissues from birth, and this represents an additional susceptibility factor. PCT develops only after hepatic UROD activity is further reduced by inhibition to less than around 20% of normal. [3] [4] [5] [6] [7] PCT is effectively treatable by either repeated phlebotomy, which decreases hepatic iron and interrupts generation of the UROD inhibitor, or 4-aminoquinoline antimalarials (chloroquine or hydroxychloroquine), which mobilize porphyrins that have accumulated in lysosomes and other organelles in hepatocytes. 1, [8] [9] [10] [11] The efficacy of both therapies is high and comparable in terms of rates of remission. 9,12 Also, we previously reported that times to remission with hydroxychloroquine 100 mg twice weekly or phlebotomy were comparable. 13 However, relapse of PCT after successful treatment occurs in some patients after each treatment, and comparative data are lacking. In this systematic review and meta-analysis we examined the frequency of PCT relapse after reported clinical remission following phlebotomy or either hydroxychloroquine or chloroquine.
Patients and methods

Search strategy
We followed the MOOSE (Meta-analysis Of Observational Studies in Epidemiology) guidelines. 14 A literature search was performed using the PubMed, Embase, Scopus, CINAHL and Cochrane databases. The initial medical subject heading search terms were 'porphyria cutanea tarda', 'phlebotomy', '4-aminoquinoline', 'chloroquine' and 'hydroxychloroquine'. All databases were searched to December 2017. References cited in these identified articles were also searched to identify additional studies that might have been missed on the initial search.
Protocol and PICO (Population Intervention Comparison Outcome) format
The population was patients with PCT achieving remission. The intervention and comparison were phlebotomy, high-dose 4-aminoquinolines or low-dose 4-aminoquinolines. The outcome was relapse of PCT defined biochemically (elevated porphyrins in plasma and/or urine) or clinically (appearance of skin lesions of PCT).
Study selection and data extraction
Eligible studies fulfilled the following criteria: (i) the study population of patients with PCT was treated with either phlebotomy or 4-aminoquinolines; (ii) data on relapse of PCT after achieving remission were reported; (iii) relapse was defined biochemically (elevation of plasma and/or urine porphyrins) or clinically (appearance of skin lesions); and (iv) the median follow-up period was ≥ 1 year. Studies with other medical interventions, review articles, interim reports, case reports and pooled analyses were excluded. Titles, abstracts and full manuscripts were reviewed independently by three authors (H.Sal., H.Sar. and A.K.S.) for selection of studies for analysis. Selected studies were reviewed independently by two investigators (H.Sal. and H.Sar.) for data extraction on patient demographics, treatment regimens and duration, and PCT remission and relapse. Any discrepancies were resolved after joint reviews of the published data and manuscripts by all authors.
End points and outcomes
The primary outcome was the pooled relapse rate (RR) during follow-up in patients who had achieved remission.
Quality assessment
The quality of the included studies was assessed independently by the first two investigators using the MINORS statement (Methodological Index for Nonrandomized Studies), which is a risk-of-bias assessment tool for nonrandomized studies. 15 Items assessed included selection of cases or cohorts and controls, comparability and information on exposure and outcome. This index provides a maximum possible score of 16 for noncomparative studies, as in this analysis, and 24 for comparative studies. The MINORS checklist was preferred over the Newcastle-Ottawa Quality Assessment Scale 16 because we included studies without a control group, and the MINORS checklist allows a quality evaluation in studies with or without a control group. Any discrepancies in the assessments by the two investigators were addressed by discussion among the investigators after further review of the manuscripts.
Statistical analysis
As the follow-up period after achieving remission was variable across studies, the median follow-up was weighted for sample size in each study to calculate the person-years of follow-up in each study, with the assumption that each patient in the study was followed for the median follow-up time. The RR for individual studies was calculated by dividing the number of relapses by the person-years of follow-up, and was recorded with the corresponding 95% confidence interval (CI). A random effects model was used to analyse pooled data for all the analyses. 17 Heterogeneity was measured using I 2 -statistics for interstudy variance, with higher I 2 -values and lower P-values suggesting higher heterogeneity. 18 Publication bias was assessed using the Egger regression and Begg-Mazumdar rank correlation tests. [19] [20] [21] The Egger test is a regression method checking for association between effect sizes and standard error and uses the actual effect size for each study. 21 The Begg-Mazumdar test is a rank correlation test examining the potential association between effect estimates (taken as a rank and not an exact effect size) and sampling variance (or standard error). 20 Funnel plots on each analysis were also developed ( Fig. S1 ; see Supporting Information). For analyses of publication bias, the analyses were repeated either by performing sensitivity analysis or using the Duval and Tweedie trim-and-fill method, which is a nonparametric (rank-based) data augmentation technique. 22 This method can be used to estimate the number of studies missing from a meta-analysis, which suppresses the most extreme results on one side of the funnel plot. It then amplifies the observed data so that the funnel plot is more symmetrical and recomputes the summary estimate based on the comprehensive data. 23 All statistical analyses were performed using the Comprehensive Meta-Analysis program (Biostat, Englewood, NJ, U.S.A.).
Results
Baseline characteristics
The initial search identified 2265 citations, of which 12 studies were included in the final analysis (Fig. 1) . These 12 studies evaluated treatment of 525 patients with PCT by phlebotomy, 4-aminoquinolines (using a low-dose regimen, defined as twice-weekly use of chloroquine 125 mg or hydroxychloroquine 100 mg, or a high-dose regimen, defined as using higher doses) or both phlebotomy and a 4-aminoquinoline. 11, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The studies were stratified into three categories based on the treatment regimen: the first group was treated with high-dose 4-aminoquinoline regimens; 11,24-27 the second with low-dose regimens; [28] [29] [30] [31] [32] and the third with repeated phlebotomies. [32] [33] [34] Data about specific dosages, phlebotomy schedules and duration of therapy are provided in Table S1 (see Supporting Information). Three studies combined high-dose 4-aminoquinoline antimalarial treatment and phlebotomy. 24, 26, 27 Also, 4-aminoquinoline regimens varied in terms of dosages, schedule and duration of treatment, and median follow-up. The number of person-years of follow-up was highest in the high-dose group, followed by the low-dose group then the phlebotomy group.
*One study included patients after remission with low-dose hydroxychloroquine as well as after remission with phlebotomy.
Records identified through searching PubMed, Embase, Scopus, CINAHL, Cochrane n = 2265
Screening
Included
Eligibility
Identification
Records after excluding reviews, case reports, editorials, animal studies n = 455
Records screened after removing duplicates n = 375
Full-text articles assessed for eligibility n = 18
Studies included in qualitative synthesis n = 12* Studies reporting relapse after remission with phlebotomy, n = 3
Studies reporting relapse after remission with high-dose 4-aminoquinolines, n = 5
Studies reporting relapse after remission with low-dose 4-aminoquinolines, n = 5 
Study quality assessment
Based on the MINORS statement, all studies had a score of 9 or higher. The clear majority of the studies fell short in detected bias and prospective sample-size calculation. All were fully published manuscripts except one. 32 33 and one scored 13 30 ( Table S2 ; see Supporting Information).
Outcomes
High-dose 4-aminoquinoline regimens
As shown in Table S1 (see Supporting Information), relapse was reported in 69 (35Á4%, range 13-67%) of the 195 patients in the five studies involving treatment with high-dose regimens of hydroxychloroquine or chloroquine. The median follow-up in these studies ranged from 2Á4 to 11 years, with a total follow-up of 1000Á1 person-years. The pooled RR was 8Á6 (95% CI 3Á9-13Á3) per 100 person-years (Fig. 2) . The data were heterogeneous (I 2 = 75%, P < 0Á01), without evidence of publication bias as assessed by the Begg-Mazumdar test (P = 0Á46) and the Egger test (P = 0Á06). Notably, the regimens in this group of five studies were quite variable, and subgroup analysis was carried out based on whether or not a preceding phlebotomy schedule was used before administering high-dose 4-aminoquinolines. The pooled RR from two studies using high-dose 4-aminoquinolines without preceding phlebotomy was 12Á2 (95% CI À0Á09 to 33Á2) per 100 person-years, with heterogeneous data (I 2 = 62%, P = 0Á1). The pooled RR from three studies using highdose 4-aminoquinolines with preceding phlebotomy was 10Á2 (95% CI 2Á5-17Á9) per 100 person-years, with heterogeneous data (I 2 = 85%, P < 0Á01). Further analyses were not done due to the low number of studies.
Low-dose 4-aminoquinoline treatment
In this group of five studies, which included 242 patients treated with low-dose 4-aminoquinoline regimens, the median follow-up ranged from 1 to 4 years, with a total of 701Á8 person-years of follow-up. Relapse was reported in 88 patients (36Á4%). The pooled RR was 17Á1 (95% CI 8Á9-25Á3) per 100 person-years (Fig. 3) . The data were heterogeneous (I 2 = 75%, P = 0Á003), with evidence of publication bias as assessed by the Egger test (P = 0Á014) but not by the Begg-Mazumdar test (P = 0Á46). Sensitivity analysis after excluding the study reported as an abstract 31 showed a similar effect size (RR 14Á5, 95% CI 7Á5-21Á5 per 100 person-years), with heterogeneous data (I 2 = 70%, P = 0Á018) and without publication bias (Egger test P = 0Á37 and Begg-Mazumdar test P = 0Á99).
Treatment by phlebotomy
Phlebotomy treatment was reported in three studies comprised of 88 patients; 18 patients (20%) relapsed during median follow-up periods ranging from 1 to 6 years, with a total of 348 person-years of follow-up. RRs among the three studies ranged from 10% to 29%. The pooled RR was 5Á1 (95% CI À0Á5 to 10Á6) per 100 person-years (Fig. 4) . The data were heterogeneous (I 2 = 66%, P = 0Á03), without evidence of publication bias as assessed by the Begg-Mazumdar test (P = 0Á09) and Egger test (P = 0Á09). Sensitivity analysis after excluding the data from the study reported only in abstract form 32 showed a similar effect size, with a pooled RR of 4Á2 (95% CI 1Á1-7Á2) per 100 person-years, with homogeneous data (I 2 = 32%, P = 0Á23).
Discussion
Phlebotomy is considered the first-line therapy for PCT at most centres, especially when the disease is associated with substantial iron overload. 7, 8, 33, [35] [36] [37] [38] [39] However, phlebotomy is expensive, time consuming, inconvenient and uncomfortable, and may cause side-effects such as syncope or anaemia. Therefore, compliance with a scheduled regimen of repeated phlebotomy is often challenging. 13 Most available evidence suggests similar rates of remission with either repeated phlebotomy or a 4-aminoquinoline regimen. Also, we found in a previous prospective study that times to remission were comparable in patients treated with low-dose hydroxychloroquine or phlebotomy. 13 However, there is less comparative information on RRs, which is an important issue in choosing treatment, but it requires long-term follow-up after treatment is completed and remission is documented. In this meta-analysis, we examined published data on RRs with these two quite different approaches to treatment of PCT. To our knowledge, this is the first meta-analysis that formally compares RRs after these treatments. We found that PCT RRs are similar for high-and low-dose 4-aminoquinoline regimens (35Á4% vs. 36Á3%), but were somewhat lower with phlebotomy (20%). Likewise, the pooled RR of PCT per 100 person-years is lowest after achieving remission with phlebotomy compared with low-or highdose 4-aminoquinolines.
It should be noted that, with few exceptions, the reports examined in this study included patients who underwent only one of these treatments, and therefore did not directly compare RRs with the alternative treatment. As a result, RRs in each study might in part reflect clinical or other reasons for choosing one type of treatment over the other. Also, the choice of treatment among the studies included in this analysis may have been affected by the presence of certain susceptibility factors or the degree of iron overload. Whether susceptibility factors -such as alcohol or oestrogen use, smoking, hepatitis C virus or HIV infection, or their removal during treatment -can influence treatment response is uncertain. However, it seems likely that the RR is especially likely to be influenced by removal, treatment or the continued presence of such factors, and this deserves attention in future prospective studies. The RR is also likely to depend on the end point chosen for discontinuation of treatment. For phlebotomy, this has been standardized by achievement of a ferritin level near the lower limit of normal. For 4-aminoquinolines, treatment is usually discontinued after normalization of porphyrin levels. The end points for both treatments and criteria for diagnosis of remission of PCT were not uniform within and across all studies we examined, and the number of studies was too small to ascertain whether such differences might influence rates of relapse.
An effect of chloroquine to increase urinary porphyrin levels and photosensitivity in patients with PCT was first reported by Davis and Ploeg in 1957, 40 and the first therapeutic uses of chloroquine in PCT were also reported in 1957. 41, 42 'High-dose' regimens of chloroquine and hydroxychloroquine correspond to standard doses used for other treatment indications, and in PCT cause a transient toxic hepatitis, with fever, nausea, vomiting, abdominal pain, headache and myalgia, [43] [44] [45] [46] accompanied by liver enzyme elevations and further marked elevation of plasma and urine porphyrins. 24, 26, [43] [44] [45] [46] [47] The transient increase in porphyrins to levels exceeding those before treatment is due to rapid mobilization of porphyrins from lysosomes and other intracellular organelles. The highest liver enzyme elevations were encountered in phlebotomized women during high-dose hydroxychloroquine treatment, with peak liver enzyme elevations on days 3-4 of treatment and normalization of enzymes by day 30. 26 Patients were usually hospitalized for such high-dose treatment regimens, 26 and development of transient ascites and haemolysis were described. 46 High-dose regimens have fallen out of favour, and low-dose regimens are more attractive due to a much lower side-effects profile. 26, 29 As an alternative to phlebotomy, we prefer a regimen of hydroxychloroquine 100 mg twice weekly until plasma and urine porphyrins are normalized, as this dose has been reported to achieve remission as rapidly as with repeated phlebotomy. 13 Although both low-dose hydroxychloroquine and phlebotomy were shown to be safe in this study, sideeffects even with this low-dose regimen may occasionally occur, and would likely be greater with somewhat higher doses.
The current meta-analysis, like others, is limited by the possibility of publication bias and subsequent overestimation of the true effect size due to negative study identification failure. 48 We combined searches from PubMed, MEDLINE, Embase and Cochrane with manual searches in order to minimize this possibility. Although we used procedures in agreement with current guidelines, we may have overlooked studies that were not accessible. 48 Another limitation is the inclusion of case-control studies, which are prone to biases in terms of case selection and reporting, and to inherent confounding factors. However, no randomized controlled studies are available, and they are unlikely to be reported comparing relapse after these treatment regimens, because patients or physicians frequently choose one or the other treatment regimen based on patient characteristics and/or preference. Also, two of the included 13 arms in the meta-analysis had a short 1-year median follow-up, 31, 32 and PCT may recur after more than 1 year. Finally, all initial analyses were heterogeneous; subgroup analysis addressed this issue except for the highdose group. Our findings of RRs of about 5-17 per 100 person-years after remission of PCT justify at least an annual follow-up visit for clinical assessment of skin lesions, for a biochemical profile for porphyrins, and to check patient compliance on control of susceptibility factors. Furthermore, the heterogeneous data as observed from these analyses clearly identify a clinical unmet need for developing homogeneous prospective longterm follow-up data to examine RRs of PCT after remission by phlebotomy or low-dose hydroxychloroquine. Properly designed studies overcoming the limitations identified in this analysis would form the basis for developing strategies and maintenance therapies to prevent such relapses. Prospective studies of well-characterized patients with PCT to examine RRs after documenting remission with phlebotomy or lowdose hydroxychloroquine are currently being conducted by the Porphyrias Consortium.
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